• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Elaggan, H., Bedewy, A., Nawar, S., Shehata, A., Hassanein, A. (2023). EXPRESSION OF INTEGRIN ALPHA7 IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS. ALEXMED ePosters, 5(4), 19-20. doi: 10.21608/alexpo.2023.244606.1716
Hanaa Abdel Meguid Elaggan; Ahmed Bedewy; Sarah Medhat Nawar; Ahmed Abdelrahman Shehata; Aya Mohamed Hassanein. "EXPRESSION OF INTEGRIN ALPHA7 IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS". ALEXMED ePosters, 5, 4, 2023, 19-20. doi: 10.21608/alexpo.2023.244606.1716
Elaggan, H., Bedewy, A., Nawar, S., Shehata, A., Hassanein, A. (2023). 'EXPRESSION OF INTEGRIN ALPHA7 IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS', ALEXMED ePosters, 5(4), pp. 19-20. doi: 10.21608/alexpo.2023.244606.1716
Elaggan, H., Bedewy, A., Nawar, S., Shehata, A., Hassanein, A. EXPRESSION OF INTEGRIN ALPHA7 IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS. ALEXMED ePosters, 2023; 5(4): 19-20. doi: 10.21608/alexpo.2023.244606.1716

EXPRESSION OF INTEGRIN ALPHA7 IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS

Article 1, Volume 5, Issue 4, December 2023, Page 19-20  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2023.244606.1716
View on SCiNiTO View on SCiNiTO
Authors
Hanaa Abdel Meguid Elaggan1; Ahmed Bedewy1; Sarah Medhat Nawar1; Ahmed Abdelrahman Shehata2; Aya Mohamed Hassanein email 1
1Department of Hematology, Medical Research Institute, Alexandria University
2Department of Hematology, Faculty of Medicine, Alexandria University
Abstract
Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell malignancy in which immature hematopoietic cells proliferate and accumulate in the bone marrow, peripheral blood and other tissues. Some patients may have the emergence of abnormal myeloid clones in the bone marrow, termed clonal hematopoiesis, years before diagnosis.
It accounts for 25% of all types of leukemia being the most common leukemia in adults, and is ranked as the sixth highest cause of death because of cancer in males worldwide. AML has greater predominance in the elderly compared to the overall population.
Integrin alpha7 (ITGA7), a member of the extracellular matrix binding proteins and one of the integrin family of adhesion molecules, is located on chromosome 12p13 and consists of over 27 exons spanning a region of about 22.5 kb. It participates in various cellular processes and has been recognized as a tumour promoter in a number of solid carcinomas.
Keywords
Acute myeloid leukemia (AML); INTEGRIN ALPHA7; response to induction chemotherapy
Supplementary Files
download 1716 19 (10) (1).pdf
Statistics
Article View: 130
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.